Overview

A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.

Status:
Completed
Trial end date:
2020-08-26
Target enrollment:
Participant gender:
Summary
To evaluate the influence of BR9006-1 and BR9006-2 on pharmacokinetics, safety, and tolerability when administered separately or co-administered to healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Treatments:
Mirabegron
Tamsulosin